Journal of Clinical Psychopharmacology最新文献_第8页

Use of Risperidone Long-Acting Injection in the Treatment of Anorexia Nervosa: A Case Report. 长效注射利培酮治疗神经性厌食症1例。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1097/JCP.0000000000001984

Ash Moradi, Emma Gill

引用次数: 0

The Role of Methylphenidate and Aripiprazole in the Treatment of Emotion Dysregulation in Children With ADHD. 哌醋甲酯与阿立哌唑治疗多动症儿童情绪失调的作用。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-16 DOI: 10.1097/JCP.0000000000002002

Pei-Yin Pan, Chin-Bin Yeh

{"title":"The Role of Methylphenidate and Aripiprazole in the Treatment of Emotion Dysregulation in Children With ADHD.","authors":"Pei-Yin Pan, Chin-Bin Yeh","doi":"10.1097/JCP.0000000000002002","DOIUrl":"10.1097/JCP.0000000000002002","url":null,"abstract":"Purpose: In this study, we examined the effectiveness of methylphenidate on emotion dysregulation among children with attention-deficit/hyperactivity disorder (ADHD), and the strategy of switching to or adding aripiprazole for nonresponders.Methods: We conducted a 3-step, 10-week, open-label trial including children (6-18 years old) with ADHD and emotion dysregulation, defined according to the Child Behavior Checklist-Dysregulation Profile. In step 1, patients received methylphenidate treatment for 4 weeks. In step 2, nonresponders were started on aripiprazole treatment for 4 weeks. Nonresponders in step 2 entered step 3, receiving a combination of methylphenidate and aripiprazole for 2 weeks. The primary outcome was the change from baseline in emotion dysregulation, assessed using the irritability subscale of the Aberrant Behavior Checklist. Secondary outcomes included the change from baseline in ADHD symptoms, cross-domain-associated symptoms, adaptive functioning, and neurocognitive profiles.Results: Among the 30 enrolled patients, 22 (73.3%) responded to methylphenidate (group MR), while 8 entered step 2 (aripiprazole treatment for methylphenidate nonresponders; group MN). In step 2, 5 patients responded to aripiprazole, while 2 patients entered step 3 and received methylphenidate plus aripiprazole. Patients who responded to methylphenidate or aripiprazole exhibited significant improvements in emotion dysregulation (Hedges' g: 2.62 and 1.30, respectively) and school adaptation. Emotion dysregulation severity was correlated with oppositional defiant disorder symptoms, but not with core symptoms of ADHD.Conclusions: The nature of emotion dysregulation in ADHD is heterogeneous regarding the response to methylphenidate. For most patients, methylphenidate significantly improved emotion dysregulation. Aripiprazole could be effective and safe for methylphenidate nonresponders.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"356-363"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review. 以智力残疾和罕见遗传变异为背景的精神分裂症患者氯氮平的使用：回顾性图表回顾。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-07 DOI: 10.1097/JCP.0000000000002000

Mark A Colijn

{"title":"Clozapine Use Among Individuals With Schizophrenia Occurring on the Background of Intellectual Disability and Rare Genetic Variation: A Retrospective Chart Review.","authors":"Mark A Colijn","doi":"10.1097/JCP.0000000000002000","DOIUrl":"10.1097/JCP.0000000000002000","url":null,"abstract":"Background: Treatment resistance in schizophrenia is associated with both intellectual disability and rare genetic variation. Information pertaining to the use of clozapine in this context has primarily come from case reports and small case series. Given the frequent occurrence of comorbid medical issues in various genetic disorders and the heightened sensitivity to antipsychotic medications among intellectually disabled individuals, additional information regarding the effectiveness and tolerability of clozapine in this population is needed, particularly in light of its unique side effect profile.Methods: This retrospective review of 1200 charts, which took place at a subspecialty psychiatry clinic, sought to characterize the use of clozapine in individuals with schizophrenia (or psychotic symptoms, generally speaking) and intellectual disability occurring on the background of rare genetic variation, a difficult to study and underserved patient population.Results: Twelve hundred charts were reviewed and 10 eligible individuals were identified, all of whom had been prescribed clozapine and carried a diagnosis of schizophrenia on the background of intellectual disability and rare genetic variation. Six of these 10 individuals harbored presumed pathogenic variants.Implications: This study affirms what is known about clozapine treatment in 22q11.2 deletion syndrome, adds to the scarce literature on Usher syndrome in this context, and provides the first accounts of clozapine use in 22q11.2 microduplication syndrome and DCX variant-related heterotopia.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"329-335"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders. 一项确定药物反应家族史是否能预测情绪障碍预后的系统综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1097/JCP.0000000000002011

Jeffrey J Rakofsky, Michael J Lucido, Boadie W Dunlop

{"title":"A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders.","authors":"Jeffrey J Rakofsky, Michael J Lucido, Boadie W Dunlop","doi":"10.1097/JCP.0000000000002011","DOIUrl":"10.1097/JCP.0000000000002011","url":null,"abstract":"Purpose/background: Examining a patient's family history of medication response is a commonly used method to inform treatment selection. Though widely recommended, there are no published reviews that assess the validity of this approach when treating patients with affective disorders.Methods/procedures: All published studies in the form of case-control or randomized controlled trials that enrolled probands with either bipolar I or II depression or major depression and were written in English were included. Studies must have also included biological relatives and must have included at least 2 families. The authors compared the methodology of each trial to a hierarchy of study designs best suited to demonstrate the predictive ability of a family history of response to a medication.Findings/results: All studies involved only a small number of participants and none of the publications included in this review used a study design that reached the highest level of study quality needed to prove the link between 2 family members' likelihood of response to a medicine. Two studies had some elements of a level I study while the remaining studies were classified at level II or III of the study hierarchy.Implications/conclusions: Although small studies suggest that a family history of drug response can predict outcome in mood disorder patients, the designs of these studies do not confirm this in a definitive manner.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"364-371"},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a Clozapine Titration Monitoring Algorithm: Integration of Evidence and Clinical Experience at a University Hospital. 开发氯氮平滴定监测算法：证据与临床经验在某大学医院的整合。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-06-09 DOI: 10.1097/JCP.0000000000002033

Emre Mutlu, Elçin Özçelik Eroğlu, M İrem Yildiz, Doğukan Koçyiğit, Aygün Ertuğrul, A Elif Anil Yağcioğlu

引用次数: 0

Exploring the Addictive Potential of Tranylcypromine: A Case Report. 探索三酰环丙胺的成瘾性：一个病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-04-07 DOI: 10.1097/JCP.0000000000001998

Livia Beraldo de Lima, Laura Fernandes Berto, Victor Hugo Spitz, João P De Aquino, Rodolfo Furlan Damiano

引用次数: 0

Semaglutide-Mediated Lithium Toxicity. semaglutide介导的锂毒性。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-05-30 DOI: 10.1097/JCP.0000000000002017

Stevyndennis Onggo, Rita Chang, Jenna Marlett, Aaliyah Zimmerman, Haylee Bettencourt, Tilden Hughes, Mina Hah

引用次数: 0

Question: Is it safe for people with cancer and other serious conditions to combine cannabidiol with melatonin when neither has worked well enough for insomnia when used alone? 问：如果大麻二酚和褪黑素单独使用对失眠都没有效果，那么癌症和其他严重疾病患者联合使用是否安全？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1097/JCP.0000000000002024

Richard I Shader

引用次数: 0

Childhood Bruxism Associated With Sertraline Dose Increase: A Case Report. 儿童期磨牙伴舍曲林剂量增加1例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1097/JCP.0000000000002016

Öznur Adigüzel Akman, Ceyda Biyikli

引用次数: 0

How Does Drug Company Marketing Affect Physician Prescribing? 制药公司的营销如何影响医生的处方？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1097/JCP.0000000000002030

Jeffrey A Mattes

引用次数: 0